Sawyers, Charles

Publication with MATCHING institution:

Mandelker D, Zhang L, Kemel Y, ..., Offit K (2017) Mutation Detection in Patients With Advanced Cancer by Universal
Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. None. [IF=None,
Cited=236, 28873162].
Fox JJ, Gavane SC, Blanc-Autran E, ..., Larson SM (2018) Positron Emission Tomography/Computed Tomography-Based
Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-
Resistant Prostate Cancer. JAMA Oncology. [IF=6.653, Cited=59, 29121144].
Abida W, Cheng ML, Armenia J, ..., Scher HI (2019) Analysis of the Prevalence of Microsatellite Instability in Prostate
Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology. [IF=6.653, Cited=266, 30589920].
Ringborg U, von Braun J, Celis J, ..., Yang H (2024) Strategies to decrease inequalities in cancer therapeutics, care
and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of
Cancer Sciences, Vatican City, February 23-24, 2023. Molecular Oncology. [IF=1.25, Cited=2, 38135904].
Schwartz S, Wongvipat J, Trigwell CB, ..., Rosen N (2014) Feedback suppression of PI3Kα signaling in PTEN-mutated tumors
is relieved by selective inhibition of PI3Kβ. Cancer Cell. [IF=5.274, Cited=146, 25544636].
Zhang Z, Zhou C, Li X, ..., Mu P (2020) Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted
Therapy via Chromatin Dysregulation. Cancer Cell. [IF=5.274, Cited=66, 32220301].
Zhang Z, Karthaus WR, Lee YS, ..., Sawyers C (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance
in Prostate Cancer. Cancer Cell. [IF=5.274, Cited=101, 32679108].
Arruabarrena-Aristorena A, Maag JLV, Kittane S, ..., Scaltriti M (2020) FOXA1 Mutations Reveal Distinct Chromatin
Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell. [IF=5.274, Cited=48, 32888433].
Gao D, Vela I, Sboner A, ..., Chen Y (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell.
[IF=8.479, Cited=819, 25201530].
Karthaus WR, Iaquinta PJ, Drost J, ..., Clevers HC (2014) Identification of multipotent luminal progenitor cells in
human prostate organoid cultures. Cell. [IF=8.479, Cited=414, 25201529].
Robinson D, Van Allen EM, Wu YM, ..., Chinnaiyan AM (2015) Integrative clinical genomics of advanced prostate cancer.
Cell. [IF=8.479, Cited=1000, 26000489].
Sawyers C (2019) Herceptin: A First Assault on Oncogenes that Launched a Revolution. Cell. [IF=8.479, Cited=16, 31519311].
Agarwal S, Hynes PG, Tillman HS, ..., Kelly K (2015) Identification of Different Classes of Luminal Progenitor Cells
within Prostate Tumors. Cell Reports. [IF=1.738, Cited=38, 26628377].
Liu X, Grogan TR, Hieronymus H, ..., Goldstein AS (2016) Low CD38 Identifies Progenitor-like Inflammation-Associated
Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports. [IF=1.738, Cited=71, 27926864].
Kim JK, Wu C, Del Latto M, ..., Smith JJ (2022) An immunocompetent rectal cancer model to study radiation therapy. Cell
Reports Methods. [IF=1.007, Cited=1, 36590695].
Luo J, Attard G, Balk SP, ..., Raj GV (2017) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017
Mission Androgen Receptor Variants Meeting. None. [IF=None, Cited=70, 29258679].
Means AL, Freeman TJ, Zhu J, ..., Beauchamp RD (2018) Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes
Inflammation-Associated Cancer. Cellular and Molecular Gastroenterology and Hepatology. [IF=1.429, Cited=34, 30109253].
Zhu B, Cao A, Li J, ..., Kaufman L (2019) Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction
in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney International. [IF=3.516, Cited=9, 31171376].
Wasmuth EV, Broeck AV, LaClair JR, ..., Sawyers C (2022) Allosteric interactions prime androgen receptor dimerization
and activation. Molecular Cell. [IF=2.773, Cited=18, 35447082].
Sun Z, Lin Y, Islam MT, ..., Helin K (2023) Chromatin regulation of transcriptional enhancers and cell fate by the Sotos
syndrome gene NSD1. Molecular Cell. [IF=2.773, Cited=5, 37402365].
Doran MG, Carnazza KE, Steckler JM, ..., Evans MJ (2016) Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of
Inhibitors to BET Bromodomain Containing Proteins. Molecular Pharmaceutics. [IF=1.039, Cited=8, 26725682].
Bose R, Karthaus WR, Armenia J, ..., Sawyers C (2017) ERF mutations reveal a balance of ETS factors controlling prostate
oncogenesis. Nature. [IF=11.591, Cited=46, 28614298].
Siu LL, Lawler M, Haussler D, ..., Voest EE (2016) Facilitating a culture of responsible and effective sharing of cancer
genome data. Nature Medicine. [IF=11.877, Cited=50, 27149219].
Sawyers C (2009) Shifting paradigms: the seeds of oncogene addiction. Nature Medicine. [IF=11.877, Cited=53, 19812578].
Drost J, Karthaus WR, Gao D, ..., Clevers H (2016) Organoid culture systems for prostate epithelial and cancer tissue.
None. [IF=None, Cited=333, 26797458].
Watson PA, Arora VK, Sawyers C (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate
cancer. Nature Reviews Cancer. [IF=10.357, Cited=735, 26563462].
Puca L, Bareja R, Prandi D, ..., Beltran H (2018) Patient derived organoids to model rare prostate cancer phenotypes.
Nature Communications. [IF=3.268, Cited=179, 29921838].
Mao N, Zhang Z, Lee YS, ..., Carver BS (2021) Defining the therapeutic selective dependencies for distinct subtypes of
PI3K pathway-altered prostate cancers. Nature Communications. [IF=3.268, Cited=12, 34417459].
Quintanal-Villalonga Á, Chan JM, Yu HA, ..., Rudin CM (2020) Lineage plasticity in cancer: a shared pathway of
therapeutic resistance. Nature Reviews Clinical Oncology. [IF=8.319, Cited=201, 32152485].
Quintanal-Villalonga Á, Chan JM, Yu HA, ..., Rudin CM (2020) Publisher Correction: Lineage plasticity in cancer: a
shared pathway of therapeutic resistance. Nature Reviews Clinical Oncology. [IF=8.319, Cited=2, 32203275].
Adams EJ, Karthaus WR, Hoover E, ..., Sawyers C (2019) FOXA1 mutations alter pioneering activity, differentiation and
prostate cancer phenotypes. Nature. [IF=11.591, Cited=119, 31243370].
Adams EJ, Karthaus WR, Hoover E, ..., Sawyers C (2020) Author Correction: FOXA1 mutations alter pioneering activity,
differentiation and prostate cancer phenotypes. Nature. [IF=11.591, Cited=0, 32895534].
Armenia J, Wankowicz SAM, Liu D, ..., Van Allen EM (2018) The long tail of oncogenic drivers in prostate cancer. Nature
Genetics. [IF=6.89, Cited=405, 29610475].
Armenia J, Wankowicz SAM, Liu D, ..., Van Allen EM (2019) Publisher Correction: The long tail of oncogenic drivers in
prostate cancer. Nature Genetics. [IF=6.89, Cited=7, 31152158].
Ganesh K, Wu C, O'Rourke KP, ..., Smith JJ (2019) A rectal cancer organoid platform to study individual responses to
chemoradiation. Nature Medicine. [IF=11.877, Cited=223, 31591597].
Sweeney SM, Lavery JA, Fuchs HE, ..., Bedard PL (2023) Addressing racial and ethnic disparities in AACR project GENIE.
npj Precision Oncology. [IF=1.415, Cited=1, 37653066].
Ajkunic A, Sayar E, Roudier MP, ..., Haffner MC (2024) Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate
cancer: Expression landscape and molecular correlates. npj Precision Oncology. [IF=1.415, Cited=1, 38760413].
Pritchard CC, Mateo J, Walsh MF, ..., Nelson PS (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic
Prostate Cancer. New England Journal of Medicine. [IF=17.194, Cited=740, 27433846].
Lawler M, Haussler D, Siu LL, ..., Sawyers C (2017) Sharing Clinical and Genomic Data on Cancer - The Need for Global
Solutions. New England Journal of Medicine. [IF=17.194, Cited=22, 28538124].
Abida W, Cyrta J, Heller G, ..., Sawyers C (2019) Genomic correlates of clinical outcome in advanced prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=609, 31061129].
Wasmuth EV, Hoover EA, Antar A, ..., Sawyers C (2020) Modulation of androgen receptor DNA binding activity through
direct interaction with the ETS transcription factor ERG. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=23, 32220959].
Feng W, Cao Z, Lim PX, ..., Sawyers C (2021) Rapid interrogation of cancer cell of origin through CRISPR editing.
Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=10, 34353917].
Zaidi S, Park J, Chan JM, ..., Sawyers C (2024) Single-cell analysis of treatment-resistant prostate cancer:
Implications of cell state changes for cell surface antigen-targeted therapies. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=1, 38968122].
Li XF, Selli C, Zhou HL, ..., Qian BZ (2023) Macrophages promote anti-androgen resistance in prostate cancer bone
disease. Journal of Experimental Medicine. [IF=2.235, Cited=13, 36749798].
Karthaus WR, Sawyers C (2019) Strategies to Identify and Target Cells of Origin in Prostate Cancer. Journal of the
National Cancer Institute. [IF=3.144, Cited=1, 30312421].
Feng W, Ladewig E, Salsabeel N, ..., Sawyers C (2024) ERG activates a stem-like proliferation-differentiation program in
prostate epithelial cells with mixed basal-luminal identity. None. [IF=None, Cited=0, 38585869].
Zaidi S, Park J, Chan JM, ..., Sawyers C (2024) Single Cell Analysis of Treatment-Resistant Prostate Cancer:
Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies. None. [IF=None, Cited=0, 38645034].
Romero R, Chu T, González-Robles TJ, ..., Sawyers C (2024) The neuroendocrine transition in prostate cancer is dynamic
and dependent on ASCL1. None. [IF=None, Cited=0, 38645223].
Wheeler DB, Zoncu R, Sabatini DM, Sawyers C (2015) Identification of an oncogenic RAB protein. Science. [IF=7.729,
Cited=80, 26338797].
Ku SY, Rosario S, Wang Y, ..., Goodrich DW (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage
plasticity, metastasis, and antiandrogen resistance. Science. [IF=7.729, Cited=567, 28059767].
Mu P, Zhang Z, Benelli M, ..., Sawyers C (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-
and RB1-deficient prostate cancer. Science. [IF=7.729, Cited=560, 28059768].
Karthaus WR, Hofree M, Choi D, ..., Sawyers C (2020) Regenerative potential of prostate luminal cells revealed by
single-cell analysis. Science. [IF=7.729, Cited=123, 32355025].
Chan JM, Zaidi S, Love JR, ..., Sawyers C (2022) Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory
signaling. Science. [IF=7.729, Cited=70, 35981096].
Quintanal-Villalonga A, Durani V, Sabet A, ..., Rudin CM (2023) Exportin 1 inhibition prevents neuroendocrine
transformation through SOX2 down-regulation in lung and prostate cancers. Science Translational Medicine. [IF=2.778,
Cited=5, 37531417].
Kaelin W, Kaelin WG, Sawyers C, ..., Mihich E (2007) Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical
investigation in cancer. Cancer Research. [IF=1.624, Cited=1, 18045966].
Jin RJ, Lho Y, Connelly L, ..., Matusik RJ (2008) The nuclear factor-kappaB pathway controls the progression of prostate
cancer to androgen-independent growth. Cancer Research. [IF=1.624, Cited=132, 18701501].
Spratt DE, Evans MJ, Davis BJ, ..., Sawyers C (2015) Androgen Receptor Upregulation Mediates Radioresistance after
Ionizing Radiation. Cancer Research. [IF=1.624, Cited=80, 26432404].
Mao N, Gao D, Hu W, ..., Carver BS (2020) Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer
Research. [IF=1.624, Cited=5, 32015092].
Tyner JW, Haderk F, Kumaraswamy A, ..., Willey CD (2022) Understanding Drug Sensitivity and Tackling Resistance in
Cancer. Cancer Research. [IF=1.624, Cited=12, 35195258].
Sawyers C, van 't Veer LJ (2014) Reliable and effective diagnostics are keys to accelerating personalized cancer
medicine and transforming cancer care: a policy statement from the american association for cancer research. Clinical
Cancer Research. [IF=2.156, Cited=10, 25204554].
Wasserman I, Lee LH, Ogino S, ..., Smith JJ (2018) SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence,
Loss of Immune Infiltrate, and Chemoresistance. Clinical Cancer Research. [IF=2.156, Cited=53, 30587545].
Duncan EA, Goetz CA, Stein SJ, ..., Baldwin AS (2008) IkappaB kinase beta inhibition induces cell death in Imatinib-
resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular Cancer Therapeutics. [IF=1.04, Cited=19, 18245668].
Lawler M, Siu LL, Rehm HL, ..., Sawyers C (2015) All the World's a Stage: Facilitating Discovery Science and Improved
Cancer Care through the Global Alliance for Genomics and Health. Cancer Discovery. [IF=3.608, Cited=32, 26526696].
Smyth LM, Zhou Q, Nguyen B, ..., Hyman DM (2020) Characteristics and Outcome of AKT1 ^E17K-Mutant
Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discovery. [IF=3.608, Cited=28, 31924700].
Leibold J, Ruscetti M, Cao Z, ..., Lowe SW (2020) Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role
for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer Discovery. [IF=3.608, Cited=31, 32376773].
Nava Rodrigues D, Rescigno P, Liu D, ..., de Bono JS (2018) Immunogenomic analyses associate immunological alterations
with mismatch repair defects in prostate cancer. Journal of Clinical Investigation. [IF=2.423, Cited=84, 30179225].
Hochhaus A, Druker B, Sawyers C, ..., Kantarjian HM (2007) Favorable long-term follow-up results over 6 years for
response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of
interferon-alpha treatment. Blood. [IF=2.983, Cited=130, 17932248].
Micheel CM, Sweeney SM, LeNoue-Newton ML, ..., Levy MA (2018) American Association for Cancer Research Project Genomics
Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member
Institutions' Perspectives. JCO clinical cancer informatics. [IF=1.626, Cited=16, 30652542].
Thomas S, Lichtenberg T, Dang K, ..., Gardos S (2020) Linked Entity Attribute Pair (LEAP): A Harmonization Framework for
Data Pooling. JCO clinical cancer informatics. [IF=1.626, Cited=1, 32755461].
Abida W, Sawyers C (2018) Targeting DNA Repair in Prostate Cancer. Journal of Clinical Oncology. [IF=6.449, Cited=1, 29369701].
Abida W, Armenia J, Gopalan A, ..., Scher HI (2017) Prospective Genomic Profiling of Prostate Cancer Across Disease
States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology.
[IF=0.968, Cited=244, 28825054].
Wise DR, Schneider JA, Armenia J, ..., Sawyers C (2020) Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-
Resistant Prostate Cancer. JCO Precision Oncology. [IF=0.968, Cited=19, 33015525].
Ogura K, Elkrief A, Bowman AS, ..., Ladanyi M (2022) Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF
and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. JCO
Precision Oncology. [IF=0.968, Cited=1, 35952322].
Ajkunic A, Sayar E, Roudier MP, ..., Haffner MC (2023) ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER:
EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES. None. [IF=None, Cited=0, 38196594].
Pappas KJ, Choi D, Sawyers C, Karthaus WR (2019) Prostate Organoid Cultures as Tools to Translate Genotypes and
Mutational Profiles to Pharmacological Responses. Journal of Visualized Experiments. [IF=0.398, Cited=10, 31710046].
Shah N, Wang P, Wongvipat J, ..., Sawyers C (2017) Regulation of the glucocorticoid receptor via a BET-dependent
enhancer drives antiandrogen resistance in prostate cancer. eLife. [IF=1.743, Cited=106, 28891793].
Settleman J, Sawyers C, Hunter T (2018) Challenges in validating candidate therapeutic targets in cancer. eLife.
[IF=1.743, Cited=17, 29417929].
Hieronymus H, Murali R, Tin A, ..., Sawyers C (2018) Tumor copy number alteration burden is a pan-cancer prognostic
factor associated with recurrence and death. eLife. [IF=1.743, Cited=151, 30178746].
Lee E, Wongvipat J, Choi D, ..., Sawyers C (2019) GREB1 amplifies androgen receptor output in human prostate
cancer and contributes to antiandrogen resistance. eLife. [IF=1.743, Cited=14, 30644358].

Publication with MISMATCHING institution:

Sawyers C, Golde DW, Quan S, Nimer SD (1992) Production of granulocyte-macrophage colony-stimulating factor in two
patients with lung cancer, leukocytosis, and eosinophilia. Cancer. [IF=2.097, Cited=39, 1540871].
Sawyers C, Denny CT, Witte ON (1991) Leukemia and the disruption of normal hematopoiesis. Cell. [IF=8.479, Cited=179, 1988151].
Sawyers C, Callahan W, Witte ON (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell. [IF=8.479,
Cited=230, 1525828].
Sawyers C, McLaughlin J, Goga A, ..., Witte O (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth.
Cell. [IF=8.479, Cited=139, 7512450].
Sawyers C, Denny CT (1994) Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell. [IF=8.479, Cited=45, 8168126].
Sawyers C (1997) Molecular genetics of acute leukaemia. The Lancet. [IF=25.787, Cited=18, 9111557].
Sawyers C (2009) Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell. [IF=8.479, Cited=10, 19490885].
Sawyers C (2001) Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Seminars in Hematology. [IF=1.062, Cited=10, 11526597].
Sawyers C (1998) Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Leukemia Research.
[IF=0.625, Cited=8, 9922075].
Sawyers C (1997) Signal transduction pathways involved in BCR-ABL transformation. None. [IF=None, Cited=26, 9376661].
Sawyers C (2002) Rational therapeutic intervention in cancer: kinases as drug targets. Current Opinion in Genetics and
Development. [IF=0.801, Cited=65, 11790564].
Sawyers C (2002) Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. [IF=5.274,
Cited=30, 12086882].
Sawyers C (2002) Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer
Cell. [IF=5.274, Cited=54, 12124170].
Sawyers C (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell. [IF=5.274, Cited=128, 14667501].
Sawyers C (2013) Perspective: combined forces. Nature. [IF=11.591, Cited=8, 23803949].
Sawyers C (2004) Targeted cancer therapy. Nature. [IF=11.591, Cited=548, 15549090].
Sawyers C (2008) The cancer biomarker problem. Nature. [IF=11.591, Cited=452, 18385728].
Hieronymus H, Iaquinta PJ, Wongvipat J, ..., Sawyers C (2017) Deletion of 3p13-14 locus spanning FOXP1 to SHQ1
cooperates with PTEN loss in prostate oncogenesis. Nature Communications. [IF=3.268, Cited=16, 29057879].
Kim JH, Kim B, Cai L, ..., Baek SH (2022) Author Correction: Transcriptional regulation of a metastasis suppressor gene
by Tip60 and β-catenin complexes. Nature. [IF=11.591, Cited=0, 35790797].
Sawyers C (1999) Chronic myeloid leukemia. New England Journal of Medicine. [IF=17.194, Cited=741, 10219069].
Sawyers C (2006) Will kinase inhibitors have a dark side? New England Journal of Medicine. [IF=17.194, Cited=24, 16855275].
Burgess MR, Skaggs BJ, Shah NP, ..., Sawyers C (2005) Comparative analysis of two clinically active BCR-ABL kinase
inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=174, 15705718].
Carter TA, Wodicka LM, Shah NP, ..., Lockhart DJ (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF
receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=293, 16046538].
Radich JP, Dai H, Mao M, ..., Linsley PS (2006) Gene expression changes associated with progression and response in
chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=355, 16477019].
Baek SH, Ohgi KA, Nelson CA, ..., Rosenfeld MG (2006) Ligand-specific allosteric regulation of coactivator functions of
androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=46, 16492776].
Mehrian-Shai R, Chen CD, Shi T, ..., Sawyers C (2007) Insulin growth factor-binding protein 2 is a candidate biomarker
for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy
of Sciences of the United States of America. [IF=2.765, Cited=124, 17372210].
Skaggs BJ, Gorre ME, Ryvkin A, ..., Graeber TG (2006) Phosphorylation of the ATP-binding loop directs oncogenicity of
drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=99, 17164333].
Watson PA, Chen YF, Balbas MD, ..., Sawyers C (2010) Constitutively active androgen receptor splice variants expressed
in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=432, 20823238].
Evans MJ, Smith-Jones PM, Wongvipat J, ..., Sawyers C (2011) Noninvasive measurement of androgen receptor signaling with
a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National
Academy of Sciences of the United States of America. [IF=2.765, Cited=165, 21606347].
Hübner A, Mulholland DJ, Standen CL, ..., Davis RJ (2012) JNK and PTEN cooperatively control the development of invasive
adenocarcinoma of the prostate. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=62, 22753496].
Hieronymus H, Schultz N, Gopalan A, ..., Sawyers C (2014) Copy number alteration burden predicts prostate cancer
relapse. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=216, 25024180].
Balbas MD, Burgess MR, Murali R, ..., Sawyers C (2014) MAGI-2 scaffold protein is critical for kidney barrier function.
Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=26, 25271328].
Roumiantsev S, Shah NP, Gorre ME, ..., Van Etten RA (2002) Clinical resistance to the kinase inhibitor STI-571 in
chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of
Sciences of the United States of America. [IF=2.765, Cited=136, 12149456].
Podsypanina K, Lee RT, Politis C, ..., Parsons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6
kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=362, 11504907].
Neshat MS, Mellinghoff IK, Tran C, ..., Sawyers C (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of
FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765, Cited=597, 11504908].
Sawyers C, Timson L, Kawasaki ES, ..., Champlin R (1990) Molecular relapse in chronic myelogenous leukemia patients
after bone marrow transplantation detected by polymerase chain reaction. Proceedings of the National Academy of Sciences
of the United States of America. [IF=2.765, Cited=55, 2405384].
Orr SL, Hughes TP, Sawyers C, ..., Hood L (1994) Isolation of unknown genes from human bone marrow by differential
screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=7, 7991548].
Raitano AB, Halpern JR, Hambuch TM, Sawyers C (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun
for transformation. Proceedings of the National Academy of Sciences of the United States of America. [IF=2.765,
Cited=217, 8524841].
Wu X, Senechal K, Neshat MS, ..., Sawyers C (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative
regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United
States of America. [IF=2.765, Cited=382, 9861013].
Whang YE, Wu X, Suzuki H, ..., Sawyers C (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human
prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of
America. [IF=2.765, Cited=376, 9560261].
Whang YE, Tran C, Henderson C, ..., Sawyers C (2000) c-Abl is required for development and optimal cell proliferation in
the context of p53 deficiency. Proceedings of the National Academy of Sciences of the United States of America.
[IF=2.765, Cited=17, 10805805].
Wu X, Hepner K, Castelino-Prabhu S, ..., Whang YE (2000) Evidence for regulation of the PTEN tumor suppressor by a
membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences
of the United States of America. [IF=2.765, Cited=243, 10760291].
Sawyers C, McLaughlin J, Witte ON (1995) Genetic requirement for Ras in the transformation of fibroblasts and
hematopoietic cells by the Bcr-Abl oncogene. Journal of Experimental Medicine. [IF=2.235, Cited=122, 7807010].
Vis DJ, Lewin J, Liao RG, ..., Voest E (2017) Towards a global cancer knowledge network: dissecting the current
international cancer genomic sequencing landscape. Annals of Oncology. [IF=8.208, Cited=16, 28453708].
Burgess MR, Sawyers C (2006) Treating imatinib-resistant leukemia: the next generation targeted therapies. The
Scientific World Journal. [IF=1.142, Cited=17, 16906325].
Sawyers C (2003) Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes and
Development. [IF=1.985, Cited=88, 14701871].
Huang CH, Lujambio A, Zuber J, ..., Lowe SW (2014) CDK9-mediated transcription elongation is required for MYC addiction
in hepatocellular carcinoma. Genes and Development. [IF=1.985, Cited=123, 25128497].
Sawyers C (2005) Making progress through molecular attacks on cancer. Cold Spring Harbor Symposia on Quantitative
Biology. [IF=0.889, Cited=22, 16869786].
Gorre ME, Mohammed M, Ellwood K, ..., Sawyers C (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL
gene mutation or amplification. Science. [IF=7.729, Cited=1000, 11423618].
Shah NP, Tran C, Lee FY, ..., Sawyers C (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science. [IF=7.729, Cited=997, 15256671].
Tran C, Ouk S, Clegg NJ, ..., Sawyers C (2009) Development of a second-generation antiandrogen for treatment of advanced
prostate cancer. Science. [IF=7.729, Cited=1000, 19359544].
Dickens M, Rogers JS, Rogers J, ..., Davis RJ (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway.
Science. [IF=7.729, Cited=403, 9235893].
Sawyers C (2001) Research on resistance to cancer drug Gleevec. Science. [IF=7.729, Cited=26, 11732550].
Suwaki N, Vanhecke E, Atkins KM, ..., Thomas GV (2011) A HIF-regulated VHL-PTP1B-Src signaling axis identifies a
therapeutic target in renal cell carcinoma. Science Translational Medicine. [IF=2.778, Cited=38, 21632985].
Senechal K, Heaney C, Druker B, Sawyers C (1998) Structural requirements for function of the Crkl adapter protein in
fibroblasts and hematopoietic cells. Molecular and Cellular Biology. [IF=1.026, Cited=45, 9710592].
Abreu-Martin MT, Chari A, Palladino AA, ..., Sawyers C (1999) Mitogen-activated protein kinase kinase kinase 1 activates
androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology. [IF=1.026,
Cited=111, 10373563].
Neshat MS, Raitano AB, Wang HG, ..., Sawyers C (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-
dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Molecular and Cellular Biology.
[IF=1.026, Cited=89, 10648603].
Chen CD, Sawyers C (2002) NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-
independent prostate cancer. Molecular and Cellular Biology. [IF=1.026, Cited=119, 11909978].
Wang MY, Lu KV, Zhu S, ..., Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal
growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research.
[IF=1.624, Cited=162, 16912159].
Young MA, Shah NP, Chao LH, ..., Kuriyan J (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in
complex with the Aurora kinase inhibitor VX-680. Cancer Research. [IF=1.624, Cited=145, 16424036].
Watson PA, Ellwood-Yen K, King JC, ..., Sawyers C (2005) Context-dependent hormone-refractory progression revealed
through characterization of a novel murine prostate cancer cell line. Cancer Research. [IF=1.624, Cited=105, 16357166].
Ellwood-Yen K, Wongvipat J, Sawyers C (2006) Transgenic mouse model for rapid pharmacodynamic evaluation of
antiandrogens. Cancer Research. [IF=1.624, Cited=15, 17079473].
Jiao J, Wang S, Qiao R, ..., Wu H (2007) Murine cell lines derived from Pten null prostate cancer show the critical role
of PTEN in hormone refractory prostate cancer development. Cancer Research. [IF=1.624, Cited=116, 17616663].
Welsbie DS, Xu J, Chen Y, ..., Sawyers C (2009) Histone deacetylases are required for androgen receptor function in
hormone-sensitive and castrate-resistant prostate cancer. Cancer Research. [IF=1.624, Cited=115, 19176386].
Clegg NJ, Wongvipat J, Joseph JD, ..., Hager JH (2012) ARN-509: a novel antiandrogen for prostate cancer treatment.
Cancer Research. [IF=1.624, Cited=342, 22266222].
Mitsiades N, Sung CC, Schultz N, ..., Scher HI (2012) Distinct patterns of dysregulated expression of enzymes involved
in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Research. [IF=1.624, Cited=138, 22971343].
Thomas GV, Horvath S, Smith BL, ..., Sawyers C (2004) Antibody-based profiling of the phosphoinositide 3-kinase pathway
in clinical prostate cancer. Clinical Cancer Research. [IF=2.156, Cited=35, 15623612].
Rosell R, Molina MA, Costa C, ..., Taron M (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in
erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research. [IF=2.156,
Cited=195, 21233402].
Horning SJ, Haber DA, Selig WKD, ..., Sawyers C (2013) Developing standards for breakthrough therapy designation in
oncology. Clinical Cancer Research. [IF=2.156, Cited=15, 23719260].
Beltran H, Hruszkewycz A, Scher HI, ..., Nelson PS (2019) The Role of Lineage Plasticity in Prostate Cancer Therapy
Resistance. Clinical Cancer Research. [IF=2.156, Cited=163, 31363002].
Wanjala J, Taylor BS, Chapinski C, ..., Carver BS (2014) Identifying actionable targets through integrative analyses of
GEM model and human prostate cancer genomic profiling. Molecular Cancer Therapeutics. [IF=1.04, Cited=20, 25381262].
Ulmert D, Evans MJ, Holland JP, ..., Sawyers C (2012) Imaging androgen receptor signaling with a radiotracer targeting
free prostate-specific antigen. Cancer Discovery. [IF=3.608, Cited=47, 22576209].
Polkinghorn WR, Parker JS, Lee MX, ..., Sawyers C (2013) Androgen receptor signaling regulates DNA repair in prostate
cancers. Cancer Discovery. [IF=3.608, Cited=307, 24027196].
Sawyers C (2008) Something lost--something gained: the ASCI begins its second century. Journal of Clinical
Investigation. [IF=2.423, Cited=0, 18382722].
Sawyers C (2008) Translational research: are we on the right track? 2008 American Society for Clinical Investigation
Presidential Address. Journal of Clinical Investigation. [IF=2.423, Cited=10, 18982165].
Gorre ME, Ellwood-Yen K, Chiosis G, ..., Sawyers C (2002) BCR-ABL point mutants isolated from patients with imatinib
mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein
90. Blood. [IF=2.983, Cited=146, 12351420].
Bhatia R, Holtz M, Niu N, ..., Forman SJ (2003) Persistence of malignant hematopoietic progenitors in chronic
myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. [IF=2.983,
Cited=350, 12576334].
Chu S, Xu H, Shah NP, ..., Bhatia R (2004) Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous
leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. [IF=2.983, Cited=123, 15345592].
Braziel RM, Launder TM, Druker BJ, ..., O'Dwyer ME (2002) Hematopathologic and cytogenetic findings in imatinib
mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. [IF=2.983, Cited=57, 12091333].
Sawyers C, Hochhaus A, Feldman E, ..., Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in
patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. [IF=2.983,
Cited=640, 11986204].
Holtz MS, Slovak ML, Zhang F, ..., Bhatia R (2002) Imatinib mesylate (STI571) inhibits growth of primitive malignant
progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. [IF=2.983,
Cited=151, 11986238].
Peng B, Hayes M, Resta D, ..., Capdeville R (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial
with chronic myeloid leukemia patients. Journal of Clinical Oncology. [IF=6.449, Cited=291, 14990650].
Scher HI, Sawyers C (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting
the androgen-receptor signaling axis. Journal of Clinical Oncology. [IF=6.449, Cited=652, 16278481].
Rathkopf DE, Morris MJ, Fox JJ, ..., Scher HI (2013) Phase I study of ARN-509, a novel antiandrogen, in the treatment of
castration-resistant prostate cancer. Journal of Clinical Oncology. [IF=6.449, Cited=137, 24002508].
Gao D, Zhan Y, Di W, ..., Chen Y (2016) A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate
and Colon. PLoS ONE. [IF=1.253, Cited=15, 27536883].
Mellinghoff IK, Sawyers C (2002) The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics.
[IF=0.636, Cited=13, 12223047].
Blattner M, Lee DJ, O'Reilly C, ..., Rubin MA (2014) SPOP mutations in prostate cancer across demographically diverse
patient cohorts. Neoplasia. [IF=1.035, Cited=101, 24563616].
Doran MG, Spratt DE, Wongvipat J, ..., Evans MJ (2014) Cabozantinib resolves bone scans in tumor-naïve mice harboring
skeletal injuries. Molecular Imaging. [IF=0.687, Cited=1, 25248353].
Sawyers C (1993) The role of myc in transformation by BCR-ABL. Leukemia and Lymphoma. [IF=0.645, Cited=22, 8251915].
Sawyers C (1993) Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leukemia and
Lymphoma. [IF=0.645, Cited=19, 8124222].
Balbas MD, Evans MJ, Hosfield DJ, ..., Sawyers C (2013) Overcoming mutation-based resistance to antiandrogens with
rational drug design. eLife. [IF=1.743, Cited=227, 23580326].
Sawyers C, Druker B (1999) Tyrosine kinase inhibitors in chronic myeloid leukemia. None. [IF=None, Cited=0, 10198725].
Sawyers C (2001) Cancer treatment in the STI571 era: what will change? Journal of Clinical Oncology. [IF=6.449,
Cited=0, 11560965].
Sawyers C, Sausville EA (2002) Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
None. [IF=None, Cited=0, 12054100].
Sawyers C (1992) The bcr-abl gene in chronic myelogenous leukaemia. None. [IF=None, Cited=0, 1451113].
Sawyers C, Gishizky ML, Quan S, ..., Witte ON (1992) Propagation of human blastic myeloid leukemias in the SCID mouse.
Blood. [IF=2.983, Cited=0, 1562735].
Sawyers C (2005) Update on the use of imatinib mesylate. Clinical Advances in Hematology and Oncology. [IF=0.382,
Cited=0, 16258483].
Sawyers C (2009) Lessons learned from the development of kinase inhibitors. Clinical Advances in Hematology and
Oncology. [IF=0.382, Cited=0, 20020670].
Sawyers C (2012) The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. None. [IF=None,
Cited=0, 23303979].

Publication with MISSING institution:

Hathorn RW, Tso CL, Kaboo R, ..., Belldegrun A (1994) In vitro modulation of the invasive and metastatic potentials of
human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer. [IF=2.097, Cited=14, 7521786].
Laitinen S, Karhu R, Sawyers C, ..., Visakorpi T (2002) Chromosomal aberrations in prostate cancer xenografts detected
by comparative genomic hybridization. Genes Chromosomes and Cancer. [IF=1.173, Cited=30, 12203791].
Chen C, Brabham WW, Stultz BG, ..., Dong JT (2001) Defining a common region of deletion at 13q21 in human cancers. Genes
Chromosomes and Cancer. [IF=1.173, Cited=23, 11433524].
Koochekpour S, Zhuang YJ, Beroukhim R, ..., Sartor O (2005) Amplification and overexpression of prosaposin in prostate
cancer. Genes Chromosomes and Cancer. [IF=1.173, Cited=35, 16080200].
Sugiyama H, Wang Y, Jackson P, ..., Klein G (1994) Molecular requirements for rapid plasmacytoma and pre-B lymphoma
induction by Abelson murine leukemia virus in myc-transgenic mice. International Journal of Cancer. [IF=1.931, Cited=0, 8014009].
Yang H, Berger F, Tran C, ..., Sawyers C (2003) MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse
xenografts. Prostate. [IF=0.814, Cited=17, 12640659].
Parsons JK, Saria EA, Nakayama M, ..., De Marzo AM (2009) Comprehensive mutational analysis and mRNA isoform
quantification of TP63 in normal and neoplastic human prostate cells. Prostate. [IF=0.814, Cited=13, 19142959].
Nandana S, Ellwood-Yen K, Sawyers C, ..., Matusik R (2010) Hepsin cooperates with MYC in the progression of
adenocarcinoma in a prostate cancer mouse model. Prostate. [IF=0.814, Cited=24, 19938013].
Berger F, Lee YP, Loening AM, ..., Gambhir SS (2002) Whole-body skeletal imaging in mice utilizing microPET:
optimization of reproducibility and applications in animal models of bone disease. European Journal of Nuclear Medicine
and Molecular Imaging. [IF=1.985, Cited=39, 12418463].
Hughes T, Martiat P, Morgan G, ..., Goldman ON (1990) Significance of residual leukaemia transcripts after bone marrow
transplant for CML. The Lancet. [IF=25.787, Cited=7, 1967352].
Scher HI, Beer TM, Higano CS, ..., Sawyers C (2010) Antitumour activity of MDV3100 in castration-resistant prostate
cancer: a phase 1-2 study. The Lancet. [IF=25.787, Cited=647, 20398925].
Paquette RL, Nicoll J, Chalukya M, ..., Rao PN (2011) Frequent EVI1 translocations in myeloid blast crisis CML that
evolves through tyrosine kinase inhibitors. Cancer genetics. [IF=0.561, Cited=18, 21872826].
Majumder PK, Grisanzio C, O'Connell F, ..., Sellers WR (2024) A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1
Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer Cell. [IF=5.274, Cited=0, 38866454].
Mellinghoff IK, Vivanco I, Kwon A, ..., Sawyers C (2004) HER2/neu kinase-dependent modulation of androgen receptor
function through effects on DNA binding and stability. Cancer Cell. [IF=5.274, Cited=224, 15542435].
Vivanco I, Palaskas N, Tran C, ..., Sawyers C (2007) Identification of the JNK signaling pathway as a functional target
of the tumor suppressor PTEN. Cancer Cell. [IF=5.274, Cited=169, 17560336].
Majumder PK, Grisanzio C, O'Connell F, ..., Sellers WR (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1
checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. [IF=5.274,
Cited=118, 18691549].
Shah NP, Kasap C, Weier C, ..., Sawyers C (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic
myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. [IF=5.274, Cited=161, 19061839].
McGillicuddy LT, Fromm JA, Hollstein PE, ..., Cichowski K (2009) Proteasomal and genetic inactivation of the NF1 tumor
suppressor in gliomagenesis. Cancer Cell. [IF=5.274, Cited=100, 19573811].
Chen Y, Sawyers C (2010) Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate
cancers. Cancer Cell. [IF=5.274, Cited=13, 20478521].
Taylor BS, Schultz N, Hieronymus H, ..., Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer
Cell. [IF=5.274, Cited=1000, 20579941].
Carver BS, Chapinski C, Wongvipat J, ..., Sawyers C (2011) Reciprocal feedback regulation of PI3K and androgen receptor
signaling in PTEN-deficient prostate cancer. Cancer Cell. [IF=5.274, Cited=786, 21575859].
Glickman MS, Sawyers C (2012) Converting cancer therapies into cures: lessons from infectious diseases. Cell. [IF=8.479,
Cited=107, 22424221].
Arora VK, Schenkein E, Murali R, ..., Sawyers C (2013) Glucocorticoid receptor confers resistance to antiandrogens by
bypassing androgen receptor blockade. Cell. [IF=8.479, Cited=573, 24315100].
Robinson D, Van Allen EM, Wu YM, ..., Chinnaiyan AM (2015) Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell. [IF=8.479, Cited=280, 28843286].
Chen Y, Sawyers C, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Current Opinion in
Pharmacology. [IF=0.854, Cited=255, 18674639].
Danila DC, Anand A, Sung CC, ..., Scher HI (2011) TMPRSS2-ERG status in circulating tumor cells as a predictive
biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. None.
[IF=None, Cited=118, 21802835].
Paquette RL, Nicoll J, Chalukya M, ..., Maciejewski J (2009) Clonal hematopoiesis in Philadelphia chromosome-negative
bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leukemia Research. [IF=0.625, Cited=4, 19804904].
Raitano AB, Whang YE, Sawyers C (1997) Signal transduction by wild-type and leukemogenic Abl proteins. None. [IF=None,
Cited=46, 9426204].
Senechal K, Sawyers C (1996) Signal transduction-based strategies for the treatment of chronic myelogenous leukemia.
None. [IF=None, Cited=4, 9015791].
Shah NP, Nicoll JM, Nagar B, ..., Sawyers C (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance
to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer
Cell. [IF=5.274, Cited=944, 12204532].
Ellwood-Yen K, Graeber TG, Wongvipat J, ..., Sawyers C (2003) Myc-driven murine prostate cancer shares molecular
features with human prostate tumors. Cancer Cell. [IF=5.274, Cited=494, 14522256].
Jung ME, Ouk S, Yoo D, ..., Wongvipat J (2010) Structure-activity relationship for thiohydantoin androgen receptor
antagonists for castration-resistant prostate cancer (CRPC). Journal of Medicinal Chemistry. [IF=1.655, Cited=98, 20218717].
Craft N, Sawyers C (None) Mechanistic concepts in androgen-dependence of prostate cancer. Cancer and Metastasis Reviews.
[IF=1.933, Cited=27, 10453286].
Yuan ZM, Huang Y, Whang Y, ..., Kufe D (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.
Nature. [IF=11.591, Cited=130, 8717045].
Sawyers C (2007) Cancer: mixing cocktails. Nature. [IF=11.591, Cited=39, 17960228].
Solit D, Sawyers C (2010) Drug discovery: How melanomas bypass new therapy. Nature. [IF=11.591, Cited=31, 21164474].
Craft N, Shostak Y, Carey M, Sawyers C (1999) A mechanism for hormone-independent prostate cancer through modulation of
androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. [IF=11.877, Cited=548, 10086382].
Kim JH, Kim B, Cai L, ..., Baek SH (2005) Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-
catenin complexes. Nature. [IF=11.591, Cited=209, 15829968].
Michor F, Hughes TP, Iwasa Y, ..., Nowak MA (2005) Dynamics of chronic myeloid leukaemia. Nature. [IF=11.591,
Cited=447, 15988530].
Chi P, Chen Y, Zhang L, ..., Sawyers C (2010) ETV1 is a lineage survival factor that cooperates with KIT in
gastrointestinal stromal tumours. Nature. [IF=11.591, Cited=207, 20927104].
Bivona TG, Hieronymus H, Parker J, ..., Sawyers C (2011) FAS and NF-κB signalling modulate dependence of lung cancers on
mutant EGFR. Nature. [IF=11.591, Cited=275, 21430781].
Hieronymus H, Sawyers C (2012) Traversing the genomic landscape of prostate cancer from diagnosis to death. Nature
Genetics. [IF=6.89, Cited=15, 22641202].
Zhang Z, Lee JC, Lin L, ..., Bivona TG (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in
lung cancer. Nature Genetics. [IF=6.89, Cited=732, 22751098].
King JC, Xu J, Wongvipat J, ..., Sawyers C (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in
prostate oncogenesis. Nature Genetics. [IF=6.89, Cited=317, 19396167].
Graeber TG, Sawyers C (2005) Cross-species comparisons of cancer signaling. Nature Genetics. [IF=6.89, Cited=13, 15624012].
Hess P, Pihan G, Sawyers C, ..., Davis RJ (2002) Survival signaling mediated by c-Jun NH(2)-terminal kinase in
transformed B lymphoblasts. Nature Genetics. [IF=6.89, Cited=109, 12161751].
Cheng EH, Sawyers C (2012) In cancer drug resistance, germline matters too. Nature Medicine. [IF=11.877, Cited=13, 22481406].
Holland JP, Evans MJ, Rice SL, ..., Lewis JS (2012) Annotating MYC status with 89Zr-transferrin imaging. Nature
Medicine. [IF=11.877, Cited=52, 23001181].
Chen Y, Chi P, Rockowitz S, ..., Sawyers C (2013) ETS factors reprogram the androgen receptor cistrome and prime
prostate tumorigenesis in response to PTEN loss. Nature Medicine. [IF=11.877, Cited=195, 23817021].
Klein KA, Reiter RE, Redula J, ..., Sawyers C (1997) Progression of metastatic human prostate cancer to androgen
independence in immunodeficient SCID mice. Nature Medicine. [IF=11.877, Cited=243, 9095173].
Mellinghoff IK, Sawyers C (2004) TORward AKTually useful mouse models. Nature Medicine. [IF=11.877, Cited=8, 15170198].
Sawyers C (2005) Calculated resistance in cancer. Nature Medicine. [IF=11.877, Cited=18, 16079872].
Sawyers C (2007) Where lies the blame for resistance--tumor or host? Nature Medicine. [IF=11.877, Cited=10, 17917659].
Thomas GV, Tran C, Mellinghoff IK, ..., Sawyers C (2005) Hypoxia-inducible factor determines sensitivity to inhibitors
of mTOR in kidney cancer. Nature Medicine. [IF=11.877, Cited=380, 16341243].
Chen CD, Welsbie DS, Tran C, ..., Sawyers C (2003) Molecular determinants of resistance to antiandrogen therapy. Nature
Medicine. [IF=11.877, Cited=1000, 14702632].
Vivanco I, Sawyers C (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer.
[IF=10.357, Cited=1000, 12094235].
Schiller G, Lee M, Miller T, ..., Territo M (1997) Transplantation of autologous peripheral blood progenitor cells
procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first
remission. Leukemia. [IF=2.198, Cited=13, 9305609].
Schiller G, Wong S, Lowe T, ..., Territo M (2001) Transplantation of IL-2-mobilized autologous peripheral blood
progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia. [IF=2.198, Cited=10, 11368436].
Paquette RL, Hsu N, Said J, ..., Glaspy JA (2002) Interferon-alpha induces dendritic cell differentiation of CML
mononuclear cells in vitro and in vivo. Leukemia. [IF=2.198, Cited=34, 12145689].
Saldanha J, Silvy M, Beaufils N, ..., Gabert J (2007) Characterization of a reference material for BCR-ABL (M-BCR) mRNA
quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia.
[IF=2.198, Cited=18, 17476280].
Kharbanda S, Pandey P, Morris PL, ..., Kufe D (1998) Functional role for the c-Abl tyrosine kinase in meiosis I.
Oncogene. [IF=1.523, Cited=27, 9583675].
Tsukasaki K, Miller CW, Greenspun E, ..., Koeffler HP (2001) Mutations in the mitotic check point gene, MAD1L1, in human
cancers. Oncogene. [IF=1.523, Cited=62, 11423979].
Gery S, Sawyers C, Agus DB, ..., Koeffler HP (2002) TMEFF2 is an androgen-regulated gene exhibiting antiproliferative
effects in prostate cancer cells. Oncogene. [IF=1.523, Cited=51, 12101412].
Thomas M, Laura R, Hepner K, ..., Banks L (2002) Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3
proteins for degradation. Oncogene. [IF=1.523, Cited=133, 12140759].
Shah NP, Sawyers C (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene.
[IF=1.523, Cited=124, 14576846].
Druker BJ, Talpaz M, Resta DJ, ..., Sawyers C (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine
kinase in chronic myeloid leukemia. New England Journal of Medicine. [IF=17.194, Cited=1000, 11287972].
Druker BJ, Sawyers C, Kantarjian H, ..., Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase
in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New
England Journal of Medicine. [IF=17.194, Cited=1000, 11287973].
Kantarjian H, Sawyers C, Hochhaus A, ..., Morra E (2002) Hematologic and cytogenetic responses to imatinib mesylate in
chronic myelogenous leukemia. New England Journal of Medicine. [IF=17.194, Cited=1000, 11870241].
Jamieson CHM, Ailles LE, Dylla SJ, ..., Weissman IL (2004) Granulocyte-macrophage progenitors as candidate leukemic stem
cells in blast-crisis CML. New England Journal of Medicine. [IF=17.194, Cited=904, 15306667].
Mellinghoff IK, Wang MY, Vivanco I, ..., Mischel PS (2005) Molecular determinants of the response of glioblastomas to
EGFR kinase inhibitors. New England Journal of Medicine. [IF=17.194, Cited=888, 16282176].
Talpaz M, Shah NP, Kantarjian H, ..., Sawyers C (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive
leukemias. New England Journal of Medicine. [IF=17.194, Cited=1000, 16775234].
Senechal K, Halpern J, Sawyers C (1996) The CRKL adaptor protein transforms fibroblasts and functions in transformation
by the BCR-ABL oncogene. Journal of Biological Chemistry. [IF=1.122, Cited=80, 8798523].
Yuan ZM, Huang Y, Fan MM, ..., Kufe D (1996) Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the
tumor suppressor protein p53. Journal of Biological Chemistry. [IF=1.122, Cited=36, 8900110].
Huang W, Shostak Y, Tarr P, ..., Carey M (1999) Cooperative assembly of androgen receptor into a nucleoprotein complex
that regulates the prostate-specific antigen enhancer. Journal of Biological Chemistry. [IF=1.122, Cited=86, 10464314].
Gera JF, Mellinghoff IK, Shi Y, ..., Lichtenstein AK (2003) AKT activity determines sensitivity to mammalian target of
rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. Journal of Biological Chemistry. [IF=1.122,
Cited=217, 14576155].
Sawyers C, Moore RD, Lerner SA, Smith CR (1986) A model for predicting nephrotoxicity in patients treated with
aminoglycosides. Journal of Infectious Diseases. [IF=1.292, Cited=54, 3701117].
Whang YE, Wu X, Sawyers C (1998) Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1
tumor suppressor gene. Journal of the National Cancer Institute. [IF=3.144, Cited=15, 9625175].
Gorre ME, Sawyers C (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current Opinion in
Hematology. [IF=0.884, Cited=58, 12042704].
Li JJ, Vasciaveo A, Karagiannis D, ..., Shen MM (2023) NSD2 maintains lineage plasticity and castration-resistance in
neuroendocrine prostate cancer. None. [IF=None, Cited=0, 37502956].
Lee E, Zhang Z, Chen CC, ..., Sawyers C (2024) Timing of treatment shapes the path to androgen receptor signaling
inhibitor resistance in prostate cancer. None. [IF=None, Cited=0, 38562884].
Afar DE, Goga A, Cohen L, ..., Witte ON (1994) Genetic approaches to defining signaling by the CML-associated tyrosine
kinase BCR-ABL. Cold Spring Harbor Symposia on Quantitative Biology. [IF=0.889, Cited=4, 7587117].
Sawyers C (2017) Dorcas Cummings Lecture. Cold Spring Harbor Symposia on Quantitative Biology. [IF=0.889, Cited=0, 28280229].
Afar DE, Goga A, McLaughlin J, ..., Sawyers C (1994) Differential complementation of Bcr-Abl point mutants with c-Myc.
Science. [IF=7.729, Cited=97, 8153630].
Cantley LC, Dalton WS, DuBois RN, ..., Steeg PS (2012) AACR Cancer Progress Report 2012. Clinical Cancer Research.
[IF=2.156, Cited=12, 22977188].
Sawyers C, Abate-Shen C, Anderson KC, ..., Weiner GJ (2013) AACR Cancer Progress Report 2013. Clinical Cancer Research.
[IF=2.156, Cited=31, 24045178].
Rodrigues DN, Rescigno P, Liu D, ..., de Bono JS (2018) Immunogenomic analyses associate immunological alterations with
mismatch repair defects in prostate cancer. Journal of Clinical Investigation. [IF=2.423, Cited=28, 30382943].
Shah NP, Skaggs BJ, Branford S, ..., Sawyers C (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-
resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation. [IF=2.423, Cited=252, 17710227].
Yoshioka T, Otero J, Chen Y, ..., Giancotti FG (2013) β4 Integrin signaling induces expansion of prostate tumor
progenitors. Journal of Clinical Investigation. [IF=2.423, Cited=67, 23348745].
Brannon AR, Sawyers C (2013) "N of 1" case reports in the era of whole-genome sequencing. Journal of Clinical
Investigation. [IF=2.423, Cited=21, 24135144].
Carethers JM, Coughlin S, Diamond B, ..., Somlo S (2014) The imperative to invest in science has never been greater.
Journal of Clinical Investigation. [IF=2.423, Cited=2, 25180532].
Druker BJ, Sawyers C, Capdeville R, ..., Goldman JM (2001) Chronic myelogenous leukemia. Hematology. American Society of
Hematology. Education Program. [IF=0.856, Cited=16, 11722980].
Ottmann OG, Druker BJ, Sawyers C, ..., O'Brien SG (2002) A phase 2 study of imatinib in patients with relapsed or
refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. [IF=2.983, Cited=313, 12200353].
Chandra J, Tracy J, Loegering D, ..., Kaufmann SH (2005) Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-
dependent and -independent imatinib resistance. Blood. [IF=2.983, Cited=49, 16291594].
Talpaz M, Silver RT, Druker BJ, ..., Sawyers C (2002) Imatinib induces durable hematologic and cytogenetic responses in
patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. [IF=2.983, Cited=536, 11877262].
Lee JC, Vivanco I, Beroukhim R, ..., Mellinghoff IK (2006) Epidermal growth factor receptor activation in glioblastoma
through novel missense mutations in the extracellular domain. PLoS Medicine. [IF=3.417, Cited=212, 17177598].
Cloughesy TF, Yoshimoto K, Nghiemphu P, ..., Sawyers C (2008) Antitumor activity of rapamycin in a Phase I trial for
patients with recurrent PTEN-deficient glioblastoma. PLoS Medicine. [IF=3.417, Cited=372, 18215105].
Clegg NJ, Couto SS, Wongvipat J, ..., Sawyers C (2011) MYC cooperates with AKT in prostate tumorigenesis and alters
sensitivity to mTOR inhibitors. PLoS ONE. [IF=1.253, Cited=57, 21394210].
Leder K, Foo J, Skaggs B, ..., Michor F (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk
of pre-existing resistance in chronic myeloid leukemia. PLoS ONE. [IF=1.253, Cited=34, 22140458].
Dahlman KB, Parker JS, Shamu T, ..., Sawyers C (2012) Modulators of prostate cancer cell proliferation and viability
identified by short-hairpin RNA library screening. PLoS ONE. [IF=1.253, Cited=16, 22509301].
Evans MJ, Holland JP, Rice SL, ..., Lewis JS (2012) Imaging tumor burden in the brain with 89Zr-transferrin. None.
[IF=None, Cited=20, 23236019].
Schiller G, Lee M, Paquette R, ..., Territo M (1999) Transplantation of autologous peripheral blood progenitor cells
procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous
leukemia in first remission. Leukemia and Lymphoma. [IF=0.645, Cited=3, 10342575].
Chen Y, Shamu T, Chen H, ..., Chi P (2011) Visualization of the interstitial cells of cajal (ICC) network in mice.
Journal of Visualized Experiments. [IF=0.398, Cited=8, 21841758].
Wang X, Scott E, Sawyers C, Friedman AD (1999) C/EBPalpha bypasses granulocyte colony-stimulating factor signals to
rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3
myeloblasts. Blood. [IF=2.983, Cited=0, 10397723].
Craft N, Chhor C, Tran C, ..., Sawyers C (1999) Evidence for clonal outgrowth of androgen-independent prostate cancer
cells from androgen-dependent tumors through a two-step process. Cancer Research. [IF=1.624, Cited=0, 10519419].
Tsingotjidou AS, Zotalis G, Jackson KR, ..., Lieberman JR (2001) Development of an animal model for prostate cancer cell
metastasis to adult human bone. Anticancer Research. [IF=0.658, Cited=0, 11396190].
Nickerson T, Chang F, Lorimer D, ..., Pollak M (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to
androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor
(IGF-IR). Cancer Research. [IF=1.624, Cited=0, 11507082].
Shah NP, Sawyers C (2001) Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of
cancer. None. [IF=None, Cited=0, 11575716].
Mellinghoff IK, Tran C, Sawyers C (2002) Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor
PKI-166 on human prostate cancer xenografts. Cancer Research. [IF=1.624, Cited=0, 12234993].
Huron DR, Gorre ME, Kraker AJ, ..., Moasser MM (2003) A novel pyridopyrimidine inhibitor of abl kinase is a picomolar
inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer
Research. [IF=2.156, Cited=0, 12684394].
Choe G, Horvath S, Cloughesy TF, ..., Mischel PS (2003) Analysis of the phosphatidylinositol 3'-kinase signaling pathway
in glioblastoma patients in vivo. Cancer Research. [IF=1.624, Cited=0, 12782577].
Waldherr C, Mellinghoff IK, Tran C, ..., Czernin J (2005) Monitoring antiproliferative responses to kinase inhibitor
therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of Nuclear Medicine. [IF=2.173, Cited=0, 15632041].
Sawyers C, Mellinghoff IK (2012) Cancer drug development. Preface. None. [IF=None, Cited=0, 23227490].
Goga A, Liu X, Hambuch TM, ..., Sawyers C (1995) p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase.
Oncogene. [IF=1.523, Cited=0, 7651743].
Shuai K, Halpern J, ten Hoeve J, ..., Sawyers C (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in
chronic myelogenous leukemia. Oncogene. [IF=1.523, Cited=0, 8710363].
Carella AM, Frassoni F, Melo J, ..., Goldman J (1997) New insights in biology and current therapeutic options for
patients with chronic myelogenous leukemia. Haematologica. [IF=1.843, Cited=0, 9299869].
Xu FH, Sharma S, Gardner A, ..., Lichtenstein A (1998) Interleukin-6-induced inhibition of multiple myeloma cell
apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood.
[IF=2.983, Cited=0, 9639523].